176 related articles for article (PubMed ID: 25035274)
1. Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.
Glassock RJ
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1341-3. PubMed ID: 25035274
[No Abstract] [Full Text] [Related]
2. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
[TBL] [Abstract][Full Text] [Related]
3. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
4. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
Li C; Li H; Wen YB; Li XM; Li XW
BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
[TBL] [Abstract][Full Text] [Related]
5. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
Guerry MJ; Vanhille P; Ronco P; Debiec H
Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
[No Abstract] [Full Text] [Related]
6. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
[TBL] [Abstract][Full Text] [Related]
9. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary membranous nephropathy: where are we now?
Angioi A; Lepori N; López AC; Sethi S; Fervenza FC; Pani A
J Nephrol; 2018 Aug; 31(4):489-502. PubMed ID: 28875476
[TBL] [Abstract][Full Text] [Related]
11. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
Brenchley PE
J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
[No Abstract] [Full Text] [Related]
12. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of primary membranous nephropathy in 2016.
van de Logt AE; Hofstra JM; Wetzels JF
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
[TBL] [Abstract][Full Text] [Related]
14. PLA2R related primary membranous nephropathy in a hepatitis C positive patient.
Ramachandran R; Yadav AK; Kumar V; Varma A; Taneja S; Nada R; Gupta KL; Jha V
Nephrology (Carlton); 2018 Mar; 23(3):288. PubMed ID: 29460999
[No Abstract] [Full Text] [Related]
15. Intravenous cyclophosphamide as an alternative to the oral cyclophosphamide modified Ponticelli regimen for high-risk PLA2R-positive membranous nephropathy.
Ștefan G; Zugravu A; Stancu S
J Nephrol; 2023 Mar; 36(2):293-295. PubMed ID: 35960429
[No Abstract] [Full Text] [Related]
16. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment.
Lai WL; Yeh TH; Chen PM; Chan CK; Chiang WC; Chen YM; Wu KD; Tsai TJ
J Formos Med Assoc; 2015 Feb; 114(2):102-11. PubMed ID: 25558821
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
Qu Z; Zhang MF; Cui Z; Wang J; Wang M; Zhang YM; Wang F; Wang X; Meng LQ; Cheng XY; Liu G; Zhao MH
Am J Nephrol; 2018; 48(6):438-446. PubMed ID: 30472708
[TBL] [Abstract][Full Text] [Related]
18. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy.
Obrisca B; Ismail G; Jurubita R; Baston C; Andronesi A; Mircescu G
Biomed Res Int; 2015; 2015():249740. PubMed ID: 26576418
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.
Gupta G; Fattah H; Ayalon R; Kidd J; Gehr T; Quintana LF; Kimball P; Sadruddin S; Massey HD; Kumar D; King AL; Beck LH
Clin Transplant; 2016 Apr; 30(4):461-9. PubMed ID: 26854647
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
